联合胰淀素类似物和GLP1受体激动剂治疗是非常有希望的减肥

IF 40 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2025-07-21 DOI:10.1038/s41574-025-01156-2

Olivia Tysoe

引用次数: 0

摘要

胰高血糖素样肽1 （GLP1）受体激动剂的发展在肥胖治疗方面取得了前所未有的进展。针对GLP1受体和其他相关受体（例如，GLP1和GIP受体双激动剂替西肽），已经开发出了非常成功的减肥和2型糖尿病（T2DM）药物。现在，肥胖治疗的另一个潜在目标正在显示出希望：胰淀素途径。REDEFINE 1是一项IIIa期双盲随机对照试验，旨在研究CagriSema对肥胖（BMI≥30 kg/m2）或超重（BMI≥27 kg/m2）且至少有一种肥胖相关合并症（非糖尿病）患者的减肥效果。该试验共涉及3,417名参与者：2,108人接受CagriSema， 302人接受semaglutide单药治疗，302人接受cagrilintide单药治疗，705人接受安慰剂。重新定义1研究的通讯作者Timothy Garvey说：“有四个随机分组：联合给药CagriSema 2.4 mg/2.4 mg，单组分包括单剂（semaglutide） 2.4 mg和（cagrilintide） 2.4 mg，以及安慰剂。”“重要的是要证明联合用药比单独使用任何一种药物都更有效，而且都优于安慰剂。”

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss

查看原文本刊更多论文

Combined amylin analogue and GLP1 receptor agonist therapies are highly promising for weight loss

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.